In this study, we report that the concurrent neutralisation of RANKL and PD‐1 by a BsAb consistently demonstrated superior anti‐tumor or anti‐metastatic control to monotherapies, even in settings in which anti‐PD‐1 or anti‐CTLA‐4 treatment alone evoked minimal anti‐tumor activities. This evidence concerns the gene TNFSF11 and neoplasm.